The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1755
May 25, 2026
View Complete Issue         Table of Contents 2019 
Yuvezzi — A Carbachol/Brimonidine Solution for Presbyopia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Yuvezzi — A Carbachol/Brimonidine Solution for Presbyopia
May 25, 2026 (Issue: 1755)
The FDA has approved Yuvezzi (Tenpoint), an ophthalmic solution containing the cholinergic agonist carbachol 2.75% and the alpha-adrenergic receptor agonist brimonidine 0.1%, for treatment of presbyopia. Carbachol and brimonidine have been...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Yuvezzi — A Carbachol/Brimonidine Solution for Presbyopia
Article code: 1755b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.